Jarrod M Patten

Jarrod M Patten (Director, MSTR) executed 11 sales totaling 22,300 shares for $3,402,892.50 on 2026-05-28 to 2026-05-29.

Director Jarrod M Patten sold 22,300 shares (44.3% of his pre-transaction holdings) across 11 separate transactions over two days in late May 2026, at prices ranging from $145.56 to $161.75 and averaging $152.60 per share. His post-transaction non-derivative holdings of 28,000 shares remain substantial, while derivative holdings (56,550 shares in three Director Stock Option vehicles) indicate he retains significant upside exposure. This sale occurs as MSTR trades at $149.78, down 67.2% from its 52-week high of $457.22 and down 15.5% over the prior 30 days, though up 12.9% over 90 days. His same-ticker history shows 5 prior trades with strong 90-day returns (ranging from +76.4% to +288.5% on buys, and a -7.5% return on a prior May 2025 sell), though the current quarterly fundamentals show $124.3M in quarterly revenue alongside a -$12.5B net loss, with full-year profitability negative. The magnitude of this two-day sale and the stock's significant drawdown from highs warrant close attention to whether this reflects conditions-based liquidity needs or other material considerations.

Director Patten purchased 23,780 shares across 2 transactions for $2,316,303.88, raising holdings to 29,335 shares; stock down 14.0% in 30 days.

Patten Jarrod M, a Director at Strategy Inc (MSTR), executed 2 separate purchases totaling 23,780 shares (23.8K shares) for $2,316,303.88 at blended average price $97.41 on 2025-10-16 and 2025-10-17. This expanded his holdings from 5,555 shares to 29,335 shares (+428.1%). The purchases occurred in a challenging market context: the stock has declined 14.0% over the past 30 days and 30.4% over 90 days, trading at $296.61 against a 52-week high of $473.83. Critically, MSTR was unprofitable over its most recent full fiscal year, and annualized revenue declined 6.6% year-over-year, while quarterly revenue stands at $114.5M. His prior 4 trades at this specific ticker showed 90-day accuracy (4 of 4 well-timed), suggesting pattern recognition; however, the company's recent profitability reversal ($10.0B net income in the latest quarter) and ongoing structural challenges (negative full-year results, revenue contraction) require investors to distinguish between insider conviction and market conditions that may not support near-term recovery.

Director Patten buys 5,555 MSTR shares at $90.00 ($500.0K); stock now $394.66, 6 insiders buying in 14 days

Patten Jarrod M, a director, purchased 5,555 shares at $90.00 on 2025-07-29 in an open-market transaction totaling $500.0K, establishing an initial position in MSTR. The purchase price of $90.00 is significantly below the current price of $394.66 and far below the 52-week high of $473.83, indicating entry near the lower end of the stock's recent trading range. This buy arrives within a 14-day cluster window in which 6 other insiders also purchased shares, suggesting coordinated accumulation by company leadership. Notably, at the same ticker, Patten's prior buy on 2025-06-05 generated a 30-day return of +375.3%, while his subsequent sells on 2025-05-30 and 2025-05-29 achieved modest positive returns of +5.3%, +4.8%, +4.3%, and +4.2% respectively, demonstrating active trading at this security. Against this backdrop, the company reported quarterly revenue of $111,066,000.00 and a net loss of $-4,217,370,000.00, with annual revenue declining 6.6% and full-year results showing negative net income, indicating material operational challenges.

Director Patten Jarrod M sold 9,550 shares for $3,501,758.75 (5 transactions) on May 29–30, reducing holdings 26.1%

Director Patten Jarrod M executed 5 separate sales totaling 9,550 shares for $3,501,758.75 at prices ranging from $364.42 to $372.00, reducing his position from 36,570 to 27,020 shares (-26.1%). The sales occurred while MSTR traded near its 52-week high ($473.83), currently trading at $372.27, down 5.6% over 30 days despite a +35.3% 90-day gain. Across his cross-ticker open-market history, Patten's prior 12 sells averaged a 90-day return of -91.1% with a 100% well-timed rate, suggesting a strong historical pattern of selling before declines. However, at this specific ticker (MSTR), his 5 most recent trades remain too recent to measure outcomes, and the company's fundamentals show net income of $-4,217,370,000 for the latest period with annual revenue decline of -6.6%, adding context to the magnitude of this liquidation.

Director Jarrod M Patten bought 10,000 shares at $101.38 and sold 650 at $371.23 on 2025-05-27, net +9,350 shares (+1438.5%).

Patten executed 2 separate transactions totaling 1 purchase of 10,000 shares for $1,013,780.00 and 1 sale of 650 shares for $241,299.50, resulting in a substantial net accumulation of 9,350 shares that raised his holdings from 650 to 10,000 shares. The purchase price of $101.38 per share represents a significant discount versus the current price of $370.63, and a substantial discount to the 52-week high of $473.83. His cross-ticker track record shows 7 prior open-market buys with an average 90-day return of +65.2% and a 100% win rate, though 5 recent same-ticker sells at MSTR on 2025-05-08 and 2025-05-29 remain unmeasurable in outcome. The company reported net income of $-4,217,370,000.00 and annual revenue decline of -6.6%, indicating fundamental headwinds, yet the director chose substantial accumulation at depressed prices relative to recent highs.

Director Jarrod M Patten sold 4,300 shares ($1.8M) at blended avg $409.25, reducing stake 31.9%; company unprofitable.

Jarrod M Patten, a Director at MicroStrategy, executed 4 separate sales totaling 4,300 shares for $1,759,785.00 across May 7–8, 2025, at prices ranging from $395.00 to $422.00. This represents a 31.9% reduction in his holdings, from 13,470 shares to 9,170 shares post-transaction. The sales occurred as the stock was +40.1% over 30 days and +27.0% over 90 days, yet MicroStrategy remains unprofitable on a full-year basis with net income of $-4,217,370,000.00 and annual revenue growth of -6.6%. Patten's cross-ticker sell track record shows a 100% well-timed rate over 13 prior sells with an average 90-day return of -91.0%, and at MSTR specifically, 2 of 2 prior measurable sells were well-timed at the 90-day mark. The combination of a substantial reduction in an insider's position during a period of elevated valuation gains, coupled with deteriorating company fundamentals and the insider's demonstrated pattern of well-timed sell timing, warrants investor attention.

Director Patten sold 3,100 MSTR shares across 3 trades for $1,132,525 on 2025-04-25; prior MSTR sells perfectly timed (5 of 5 at 90d)

Jarrod M Patten (Director) executed 3 separate sales totaling 3,100 shares for $1,132,525 at blended average $365.33, reducing holdings by 30.5% to 7,070 shares. His prior trades at MSTR show an exceptional pattern: 5 of 5 prior sells were well-timed at the 90-day mark with negative returns ranging from -90.8% to -91.3%, indicating he has consistently sold before subsequent declines at this specific company. His cross-ticker track record reveals 13 prior sells with a 100% well-timed rate and average 90-day return of -91.1%, further demonstrating systematic precision in sell timing across markets. The current stock price of $381.45 is -19.5% from the 52-week high of $473.83, and fundamentals show the company was unprofitable in its most recent full fiscal year with net income of $-340,174,000 and annual revenue growth of -6.6%, creating a context where this insider's historical pattern of well-timed selling becomes particularly relevant to investor assessment.

Director Patten bought 2,240 CORZ shares at $11.05 on 2024-09-13; 5 consecutive CORZ buys in 11 days amid -21.5% YoY revenue decline.

Jarrod M Patten, a director, purchased 2,240 shares at $11.05, bringing his total holdings to 300,000 shares. This transaction is the fifth consecutive open-market buy at Core Scientific in 11 days (buys on 2024-08-30, 2024-09-03, 2024-09-04, 2024-09-10, and 2024-09-11), each outcomes not yet measurable at 30 and 90 days. The timing of this concentrated buying activity occurs as the company faces material headwinds: annual revenue declined -21.5% year-over-year, and the company posted a net loss of $804.9M against quarterly revenue of $141.1M, confirming unprofitability over the most recent full fiscal year. The stock is currently at $11.18, within 4.4% of its 52-week high of $11.70, having risen 10.8% over 30 days and 25.5% over 90 days. The repeated accumulation pattern during a period of operational contraction merits investor scrutiny, particularly given the lack of measurable outcomes from the prior same-ticker buys and the company's negative earnings profile.

Director Jarrod M Patten buys 2,100 shares of CORZ at $10.10; 5th buy in 9 days amid -21.5% annual revenue decline and -$804.9M net loss.

Patten acquired 2,100 shares at $10.10 on 2024-09-11, marking his fifth consecutive open-market purchase at Core Scientific in a span of nine calendar days (2024-08-28 through 2024-09-11). The company faces material headwinds: annual revenue contracted 21.5% year-over-year, and most recent full-year net income was -$804.9M against $141.1M quarterly revenue, underscoring profitability challenges. Current trading price of $10.39 sits 11.2% below the 52-week high and reflects a +22.8% rebound over the prior 30 days. His cross-ticker track record shows 15 prior sells with a 100.00% well-timed rate at the 90-day mark, but this metric—measuring how often his sale exits preceded declines—does not directly inform buy-side conviction or accuracy at CORZ, where five recent acquisitions remain early-stage and unmeasurable on outcome metrics.

Director Patten Jarrod M bought 2,100 CORZ shares at $9.90; now holds 295.7K shares amid 5 consecutive buys in Sept 2024.

Patten purchased 2,100 shares at $9.90 on 2024-09-10, bringing his total holdings to 295.7K shares. This is the most recent in a sequence of 5 consecutive buys at this ticker spanning 2024-08-28 through 2024-09-11, collectively showing sustained accumulation. At the transaction price of $9.90, the stock was already trading 14.8% below its 52-week high of $11.70, and the 30-day price change of +5.3% suggests some recent recovery from lower levels. However, Core Scientific reported negative net income of $-804.9M on revenue of $141.1M, with annual revenue declining 21.5% year-over-year, indicating material operational challenges. The director's prior cross-ticker history shows 15 sells with a 90-day well-timed rate of 100.0%, but at CORZ specifically, none of the 5 prior measurable buys showed positive 90-day returns—a pattern inconsistent with the cross-ticker track record. The sustained buying activity during a period of negative earnings and declining revenue suggests the director is accumulating despite deteriorating fundamentals.